Cadence Pharmaceuticals Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 210

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.33B

Cadence Pharmaceuticals General Information

Description

Developer of proprietary product candidates principally for use in hospital settings. The company has rights to one product candidate, Ofirmev, a proprietary intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 12481 High Bluff Drive
  • Suite 200
  • San Diego, CA 92130
  • United States
+1 (858)
Primary Industry
Pharmaceuticals
Vertical(s)
Corporate Office
  • 12481 High Bluff Drive
  • Suite 200
  • San Diego, CA 92130
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cadence Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 19-Mar-2014 $1.33B Completed Generating Revenue
6. Debt - General 21-Jun-2010 Completed Generating Revenue
5. PIPE 19-Feb-2009 Completed Generating Revenue
4. IPO 25-Oct-2006 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series A3) 22-Feb-2006 Completed Product Development
2. Early Stage VC (Series A2) 11-Oct-2005 $17.7M $25.3M Completed Product Development
1. Early Stage VC (Series A1) 01-Aug-2004 $7.6M $7.6M Completed Product Development
To view Cadence Pharmaceuticals’s complete valuation and funding history, request access »

Cadence Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3
Series A2
Series A1 8,085,108 8% $0.94 $0.94 $0.94 9.89%
To view Cadence Pharmaceuticals’s complete cap table history, request access »

Cadence Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of proprietary product candidates principally for use in hospital settings. The company has rights to one prod
Pharmaceuticals
San Diego, CA
210 As of 2013

Tokyo, Japan
 

Baton Rouge, LA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cadence Pharmaceuticals Competitors (3)

One of Cadence Pharmaceuticals’s 3 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Astellas Pharma Corporation Tokyo, Japan
OncBioMune Pharmaceuticals Corporate Backed or Acquired Baton Rouge, LA
Knoa Pharma Corporate Backed or Acquired Stamford, CT
You’re viewing 3 of 3 competitors. Get the full list »

Cadence Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cadence Pharmaceuticals Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
BB Biotech Ventures Venture Capital Minority
Bay City Capital Venture Capital Minority
CDIB BioScience Venture Management Venture Capital Minority
Domain Associates Venture Capital Minority
Frazier Healthcare Partners PE/Buyout Minority
You’re viewing 5 of 13 investors. Get the full list »

Cadence Pharmaceuticals Investments (1)

Cadence Pharmaceuticals’s most recent deal was a Early Stage VC with Incline Therapeutics for . The deal was made on 13-Sep-2011.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Incline Therapeutics 13-Sep-2011 Early Stage VC Drug Discovery
To view Cadence Pharmaceuticals’s complete investments history, request access »

Cadence Pharmaceuticals FAQs

  • When was Cadence Pharmaceuticals founded?

    Cadence Pharmaceuticals was founded in 2004.

  • Where is Cadence Pharmaceuticals headquartered?

    Cadence Pharmaceuticals is headquartered in San Diego, CA.

  • What is the size of Cadence Pharmaceuticals?

    Cadence Pharmaceuticals has 210 total employees.

  • What industry is Cadence Pharmaceuticals in?

    Cadence Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Cadence Pharmaceuticals a private or public company?

    Cadence Pharmaceuticals is a Private company.

  • What is the current valuation of Cadence Pharmaceuticals?

    The current valuation of Cadence Pharmaceuticals is .

  • What is Cadence Pharmaceuticals’s current revenue?

    The current revenue for Cadence Pharmaceuticals is .

  • How much funding has Cadence Pharmaceuticals raised over time?

    Cadence Pharmaceuticals has raised $223M.

  • Who are Cadence Pharmaceuticals’s investors?

    BB Biotech Ventures, Bay City Capital, CDIB BioScience Venture Management, Domain Associates, and Frazier Healthcare Partners are 5 of 13 investors who have invested in Cadence Pharmaceuticals.

  • Who are Cadence Pharmaceuticals’s competitors?

    Astellas Pharma, OncBioMune Pharmaceuticals, and Knoa Pharma are competitors of Cadence Pharmaceuticals.

  • When was Cadence Pharmaceuticals acquired?

    Cadence Pharmaceuticals was acquired on 19-Mar-2014.

  • Who acquired Cadence Pharmaceuticals?

    Cadence Pharmaceuticals was acquired by Mallinckrodt Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process